echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Difficulties in R & D of new drugs in A-share listed pharmaceutical companies

    Difficulties in R & D of new drugs in A-share listed pharmaceutical companies

    • Last Update: 2015-07-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: on July 6, 2015, new traditional Chinese medicine similar to Kanglaite anticancer injection rarely appeared in the international market, and the traditional Chinese medicine, which accounts for half of China's pharmaceutical industry, is still hard to develop Due to the complex composition of traditional Chinese medicine, restricted by technical, financial and talent barriers, few domestic listed pharmaceutical companies involve in new drug research and development One industry person said that the root of new drug research and development of traditional Chinese Medicine - "in the final analysis, it is the serious imbalance between the input and output of new drug research and development." At present, the R & D expenditure of domestic listed pharmaceutical companies is extremely stingy The reporter of Changjiang business daily combed several research papers of listed pharmaceutical companies and found that most of their R & D expenditure was less than 2%, while the proportion of sales expenses was 10% or more The reporter of Changjiang business daily learned that the low-cost production of Western medicine still occupies an important position in the product structure of the enterprise Focusing on sales and neglecting research and development has become a common problem of domestic listed pharmaceutical enterprises The thinking of making fast money and making fast money occupies the head of the enterprise and lacks long-term planning On July 3, the research and development of drugs are mostly "replacing the old with the new" Wu Hezhen, deputy director of science and Technology Department of Hubei University of traditional Chinese medicine and doctoral director, told Changjiang business daily in an exclusive interview that at present, the large cycle investment in new drug research and development and the low passing rate of review lead to the enterprise's flinch The shortest time for general Chinese medicine products from preliminary research to project approval and marketing is also 6 After entering the market, there is also the risk of running in with the market In view of this, most pharmaceutical companies will not make great efforts to develop new drugs The reporter of Changjiang business daily noted that pharmaceutical enterprises with old prescriptions will generally improve their old products and launch new ones For example, Ma Yinglong launched the second generation of Ma Yinglong musk Hemorrhoid Cream as a traditional Chinese medicine product, and Ma Yinglong has a share of 45% in the retail market of hemorrhoid drugs, but the latest 10 newly developed products only have one important product, which is still an improved product Hunan Qianjin Pharmaceutical Co., Ltd focuses on women's health industry According to the 2013 annual report, it is necessary to complete the preparation for the market of new dosage forms such as Fukeqianjin pill and buxueyimu pill, and start the clinical reevaluation of Fukeqianjin capsule The clinical trial of buconazole Ⅱ B nitrate is advancing in an orderly manner, and the pharmaceutical research of bianjuniaiyan granules, a six class new Chinese medicine, has been completed This means that there is still a long way to go before new drugs come to market In the 2014 annual report of Jianmin group, it shows that the company has "reexamined and examined scientific research resources" and completed the application and production of kaiyuning tablet, a new Chinese medicine of 5 categories, in 2014; the second phase clinical research of Xiaoer Xuanfei syrup, Xiaoer niuhuangtie hot patch and Liwei capsule has been completed and entered the third phase Phase I clinical phase; Azithromycin sustained-release dry suspension and other varieties completed the pre clinical research preparation for clinical application; the new project of children's constipation granules and other projects progressed smoothly, and the new product development echelon pattern gradually formed The second development of old products by Jianmin group also appeared in the annual report, mainly focusing on the second research and development direction of "efficacy, quality, taste, indications", etc., continue to carry out technical research and technological improvement on the company's leading products and key products Compared with the over cautious R & D pattern of the above-mentioned companies, Kanglaite anticancer injection has spent 1.2 billion yuan to enter the international market after 20 years, which may be a big deal A number of listed pharmaceutical companies attach importance to sales rather than research and development, and domestic listed pharmaceutical companies attach different importance to research and development The reporter of Changjiang business daily combed the data of Yunnan Baiyao, Ma Yinglong, Qianjin pharmaceutical and other listed pharmaceutical companies, and their R & D expenditure was generally within 2% of the total revenue Yunnan Baiyao (securities code: 000538) is an important national protection brand, with many classified traditional Chinese medicine According to the 2014 annual report, the total R & D expenditure in the reporting period was 158640000 yuan, a decrease of 23.14 million yuan over the previous year, accounting for 0.84% of the company's operating revenue In the same period of 2013, Yunnan Baiyao R & D expenditure accounted for 2.01% of the company's net assets Ma Yinglong (security code: 600993) is a pharmaceutical enterprise in Hubei Province, whose R & D expenses have decreased significantly in the past two years According to the company's annual report, the R & D expenditures in 2014 and 2013 were 28.4478 million yuan and 30.5187 million yuan respectively Among them, R & D expenditure accounted for 3.51% of the pharmaceutical industry's revenue in 2014 However, the reporter found that only one of the 10 key R & D projects of the company in 2015 was the second generation of Ma Yinglong musk Hemorrhoid Cream, which was a traditional Chinese medicine product, and the other nine were chemicals Qianjin tablet (capsule), the leading product of Qianjin Pharmaceutical (securities code: 600479) in Hunan Province, is a category a variety of national traditional Chinese medicine protection and national basic medical insurance catalogue It is the only category of Chinese traditional medicine for gynecology listed in the state secret technology Although the company's R & D expenditure increased by 31.08% in 2014, it only accounted for 2.20% of the operating revenue in that year, and the R & D expenditure accounted for 1.86% of the operating revenue in 2013 On July 3, Xie Aiwei, Secretary of board of directors of Qianjin Pharmaceutical Co., Ltd., responded to the reporter of Changjiang Business Daily that "the company's R & D investment keeps growing, and the rate of R & D expenses keeps rising is not changed much, mainly due to the growth of business income in the consolidated statements." The reporter of Changjiang business daily noted that in terms of the sales expense rate of listed pharmaceutical companies, in 2013 and 2014, except for Yunnan Baiyao, the sales expense rates of Qianjin pharmaceutical, Ma Yinglong, Jiuzhitang, Guilin Sanjin and Jiangzhong pharmaceutical were all between 20% and 30% In terms of R & D investment, in 2013 and 2014, the R & D expenditure of the above-mentioned pharmaceutical enterprises accounted for less than 2% of the operating revenue The pharmaceutical market is changing rapidly, and the investment in research and development is small, which means that the new drug reserve may be insufficient in the future Wu Hezhen has repeatedly advised pharmaceutical companies to provide a certain amount of funds for new drug research and development reserve every year, but few people should In the view of Li Hu, a researcher of China Research Institute and PricewaterhouseCoopers, enterprises despise the impact of R & D on the future sustainable profitability, and entrepreneurs lack a long-term vision, which is essentially caused by the difficulty in balancing the input and output of new drug R & D at present New drug R & D needs to break the financial barriers It is worth noting that at present, a large number of patented drugs of foreign pharmaceutical enterprises have expired, the limitations of chemical drugs have become more and more obvious, and the selectivity is very limited, while the difficulty and failure rate of new drug research and development of Western medicine are increasing, the cycle and cost continue to rise, western countries gradually increase investment in the field of traditional Chinese medicine, and the control of Chinese patent medicine in China is also beginning to loosen, which also makes the development of traditional Chinese medicine industry And application is becoming one of the development directions of pharmaceutical products in the world However, due to factors such as limited investment, scattered use of funds, and difficult transformation of achievements, scientific and technological innovation is very weak At the same time, western traditional Chinese medicine has grasped the "bull's nose" of scientific and technological innovation, which directly leads to the trade deficit between Chinese patent medicine export and Western Traditional Chinese medicine import for three consecutive years In terms of research and development, drug research was still one of the most time-consuming research in the field of science and technology in that year The huge amount of investment in research and development cost made the drug look forward As a big country of traditional Chinese medicine resources, in this situation, intellectual property protection and important quality control become a very important part of technology According to Wu Hezhen, traditional Chinese medicine is a resource-based industry At present, the lack of industrial planning and standardized planting of traditional Chinese medicine in China leads to differences in the quality of traditional Chinese medicine due to environmental differences in climate, ecology and soil, which affects the stability of efficacy Taking Hubei Province as an example, Luotian County in the East is the main Poria producing area, and the west is the important producing area of Coptis chinensis After the introduction of such planting plan, effective management and scientific planting can be conducted in different areas In addition, more efforts should be made in the protection of intellectual property in China On July 3, Chen Xuejun, science and Technology Department of Hubei Provincial Hospital of traditional Chinese medicine, told Changjiang Business Daily that the number of outpatient clinics of traditional Chinese medicine in recent years has continued to rise, which shows that traditional Chinese medicine is further recognized by people, and it is indeed effective for some diseases Unfortunately, the hospital seldom participates in the research and development of new drugs, mainly to undertake national key projects and clinical trials According to Li Hu, the traditional Chinese medicine industry has always been a traditional dominant industry in China, occupying half of China's pharmaceutical industry with its advantages of large output, wide distribution and small side effects However, for enterprises, the barriers of technology, capital and talent are relatively high Currently, the top 10 pharmaceutical enterprises in the world spend more than 7 billion US dollars on new drug research and development every year The research and development funds alone are not affordable for domestic general pharmaceutical enterprises He believes that in the future, the state should increase policy and financial support for pharmaceutical enterprises; with the expiration of a large number of patented drugs in western countries, increase the production of related generic drugs; increase the training of relevant technical personnel, and actively layout the latest frontier research and development technology.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.